Estimating Strain‐Specific and Overall Efficacy of Polyvalent Vaccines Against Recurrent Pathogens From a Cross‐Sectional Study
Evaluating vaccine efficacy for protection against colonization with bacterial pathogens is an area of growing interest. Colonization of the nasopharynx is an asymptomatic carrier state responsible for person‐to‐person transmission. It differs from most clinical outcomes in that it is common, recurr...
Saved in:
Published in | Biometrics Vol. 69; no. 1; pp. 235 - 244 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
England
Blackwell Publishers
01.03.2013
Blackwell Publishing Ltd Wiley-Blackwell |
Subjects | |
Online Access | Get full text |
ISSN | 0006-341X 1541-0420 1541-0420 |
DOI | 10.1111/j.1541-0420.2012.01826.x |
Cover
Loading…
Summary: | Evaluating vaccine efficacy for protection against colonization with bacterial pathogens is an area of growing interest. Colonization of the nasopharynx is an asymptomatic carrier state responsible for person‐to‐person transmission. It differs from most clinical outcomes in that it is common, recurrent, and observed only in its prevalent state. To estimate rates of acquisition and clearance of colonization requires repeated active sampling of the same individuals over time, an expensive and invasive undertaking. Motivated by feasibility constraints in efficacy trials with colonization endpoints, investigators have been estimating vaccine efficacy from cross‐sectional studies without principled methods. We present two examples of vaccine studies estimating vaccine efficacy from cross‐sectional data on nasopharyngeal colonization by Streptococcus pneumoniae (pneumococcus). This study presents a framework for defining and estimating strain‐specific and overall vaccine efficacy for susceptibility to acquisition of colonization () when there is a large number of strains with mutual interactions and recurrent dynamics of colonization. We develop estimators based on one observation of the current status per study subject, evaluate their robustness, and re‐analyze the two vaccine trials. Methodologically, the proposed estimators are closely related to case–control studies with prevalent cases, with appropriate consideration of the at‐risk time in choosing the controls. |
---|---|
Bibliography: | http://dx.doi.org/10.1111/j.1541-0420.2012.01826.x ark:/67375/WNG-H8KT6SFG-P ArticleID:BIOM1826 istex:EEE51352505B0A6FE5919BC3D4C0203632F1F428 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ISSN: | 0006-341X 1541-0420 1541-0420 |
DOI: | 10.1111/j.1541-0420.2012.01826.x |